COVID-19 Startups funded by Y Combinator (YC) 2026

Digital health holds a lot of potential but is ignoring a growing problem: diagnostic testing. Without this data, providers and organizations will be limited in the services they can provide patients at home. Scout has developed a platform - Hub, test kits, and app - that delivers health testing at home with 10x lower development cost and 3x lower per-test price. Our patented tech also meets performance requirements for medical diagnoses and integrates with the current healthcare tech stack. Scout’s technology is poised to disrupt the outdated $33Bn diagnostic market by democratizing testing while dramatically improving the patient experience. Scout has received $16M in non-dilutive funding from the NIH and other organizations to fully de-risk our platform, and our pipeline includes a diverse test menu for primary care (e.g. respiratory and sexual health), wellness (e.g. gut health), and chronic conditions (e.g. certain cancers). We have already received FDA authorization for our platform in clinical settings and are planning to launch our flagship Scout Hub in 2024.

PostEra is building a modern 21st century biopharma. We're using our advances in machine learning to accelerate Medicinal Chemistry and bring more cures to patients. PostEra advances small molecule programs through partnerships with biopharma while also advancing its own internal pipeline. We've raised $26M from top investors and closed $1Bn in AI partnerships, signing multi-year agreements with Amgen, Pfizer and the NIH. PostEra also launched and led the world's largest open-science drug discovery effort; COVID Moonshot.

Persephone Biome develops live biotherapeutic products to modulate the metabolism of gut microbes, for applications in disease prevention and cure. We take a unique engineering approach using systems and synthetic biology to understand the complexities of the microbiome.